Partner Abbie Celniker named among Boston Business Journal's 2017 Innovation All-stars

Read More

Congratulations to Voyager Therapeutics on being named one of The Boston Globe's 2016 Top Places to Work

Read More

Third Rock launches Magenta Therapeutics with $48.5M to Apply New Stem Cell Science to Reboot the Immune System

Read More

Allergan to Acquire Motus Therapeutics

Read More

Third Rock Ventures Raises $616 million Oversubscribed Fund

Read More

Partner Profile: Charles Homcy

Read More

Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company

Read More

Congratulations to our Fierce 15 winners Rhythm, Fulcrum and Neon

Read More

Third Rock launches Relay Therapeutics with $57M to build the world’s first dedicated drug discovery platform centered on protein motion

Read More

Jounce and celgene to collaborate on next-generation immuno-oncology therapies

Read More

Third Rock Launches Fulcrum Therapeutics to Transform Gene Regulation in Disease

Read More

Decibel Therapeutics Appoints Steven H. Holtzman as President and Chief Executive Officer

Read More

Merck to Acquire Afferent for up to $1.25 billion

Read More

Take a look at what we’ve been up to for the past 8+ years

Watch the Video

Sign up for weekly portfolio company news alerts here
 

Read More

Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock

Watch the Video

Transforming Healthcare

42

Portfolio Companies
With More Than $1.9 Billion
Under Management

45

Clinical Studies
Underway Within Our Portfolio

60

Diseases
Being Targeted By
Our Companies

10  

of thousands

Patients Impacted
By Portfolio Company Products
and Clinical Trials